Humana Inc. 10-Q Summary: Q2 2025
Business Context and Reporting Period
This summary covers Humana Inc.'s unaudited financial results for the quarterly period ended June 30, 2025. Humana operates two primary reportable segments: Insurance (Medicare Advantage, Medicaid, and specialty benefits) and CenterWell (pharmacy, primary care, and home solutions). The company is a large accelerated filer headquartered in Louisville, Kentucky.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $32,388 million | $29,540 million | $64,500 million | $59,151 million |
| Net Income (Attributable to Humana) | $545 million | $679 million | $1,789 million | $1,420 million |
| Diluted EPS | $4.51 | $5.62 | $14.81 | $11.74 |
| Operating Cash Flow (YTD) | $1,602 million (2025) vs $1,636 million (2024) | |||
| Cash & Equivalents (End of Period) | $4,040 million (June 30, 2025) | |||
| Long-Term Debt | $12,586 million (June 30, 2025) | |||
| Benefit Ratio | 89.7% | 89.0% | 88.4% | 88.9% |
| Operating Cost Ratio | 11.0% | 10.8% | 10.8% | 10.6% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 9.6% quarter-over-quarter and 9.0% year-to-date, driven by higher per-member Medicare premiums (due to Inflation Reduction Act subsidies) and growth in state-based contracts and stand-alone PDP businesses.
- Profitability Decline (Q2): Net income decreased 20% in Q2 2025 compared to Q2 2024. This decline was significantly impacted by $200 million in put/call valuation adjustments related to non-consolidating minority interest investments, $32 million in impairment charges, and $29 million in value creation initiative charges.
- Profitability Growth (YTD): Despite Q2 headwinds, YTD net income increased 26% due to strong performance in the first half of the year and lower impairment charges compared to the prior year.
- Membership Shifts: Individual Medicare Advantage membership decreased by 6.9% (388,300 members) due to strategic exits from unprofitable plans. Conversely, State-based contracts grew 13.7% and Medicare stand-alone PDP grew 3.7%.
- Debt Management: In March 2025, the company issued $1.5 billion in new senior notes to repay maturing debt and fund general corporate purposes. Long-term debt increased to $12.6 billion.
Guidance, Outlook, and Risks
- Value Creation Initiatives: Management expects to incur additional charges in 2025 related to asset impairments, severance, and consulting as part of cost-saving and productivity initiatives.
- Regulatory Risks (RADV): A significant contingency involves the Centers for Medicare & Medicaid Services (CMS) Risk-Adjustment Data Validation (RADV) audits. CMS has eliminated the "FFS Adjuster" and plans to extrapolate audit results for payment years 2018–2024. Humana is litigating this rule, arguing it violates the Administrative Procedure Act. The outcome could materially affect financial results.
- Legal Proceedings: The company faces a stockholder class action regarding financial performance disclosures and a DOJ-intervened qui tam lawsuit regarding non-commission payments to brokers. Humana intends to vigorously defend these matters.
- Star Ratings Litigation: Humana has refiled a lawsuit challenging CMS Star Rating policies, seeking to vacate 2025 ratings and remand for recalculation.
- Liquidity: The company maintains a BBB credit rating and has $4.985 billion of remaining borrowing capacity under its revolving credit agreement. Management believes current resources are adequate for the next 12 months.
Investor Verification Checklist
- Put/Call Valuation Volatility: Verify the sensitivity of the $1.25 billion put liability and $13 million call asset related to the Welsh, Carson, Anderson & Stowe (WCAS) partnership, as valuation changes significantly impacted Q2 earnings.
- RADV Audit Exposure: Assess the potential financial impact of CMS extrapolating RADV audit results without the FFS Adjuster for PY 2018–2024, given the company's active litigation.
- Membership Mix Impact: Monitor the long-term profitability implications of the 6.9% decline in Individual Medicare Advantage membership versus the growth in higher-benefit-ratio state-based contracts.
- Impairment Charges: Track future "Value Creation Initiative" charges, as management indicated additional charges are expected in 2025.
- Debt Maturity Profile: Review the schedule of senior notes maturities and the company's strategy for refinancing or repurchasing debt, particularly the 1.350% and 3.950% notes maturing in 2027.